Key Takeaways
- Eli Lilly’s triple-receptor candidate retatrutide successfully completed its initial Phase 3 study in Type 2 diabetes
- The drug reduced HbA1c levels by 1.7%â2% compared to 0.8% with placebo over a 40-week period
- Study participants experienced up to 16.8% body weight reduction at the maximum dose level
- The medication activates three hormone pathways (GLP-1, GIP, glucagon) compared to one or two in current therapies
- Regulatory filing has not been submitted yet; seven additional Phase 3 studies are anticipated to report results this year
Eli Lilly reported Thursday that its investigational medication retatrutide successfully achieved the primary endpoint in its inaugural late-stage diabetes study, demonstrating significant reductions in blood glucose levels alongside substantial weight reduction in Type 2 diabetes patients.
The study, which ran for 40 weeks, evaluated retatrutide in Type 2 diabetes patients who were controlling their disease solely through lifestyle modifications including diet and physical activity. Participants began the trial with baseline HbA1c measurementsâa key indicator of average blood glucoseâranging from 7% to 9.5%.
Across all tested dosages, retatrutide delivered HbA1c reductions averaging between 1.7% and 2%, significantly outperforming the 0.8% reduction observed with placebo. This outcome satisfied the study’s primary objective.
Regarding weight reduction, participants receiving the maximum dose experienced an average 16.8% decrease in body weight among those who completed treatment. In the intention-to-treat analysisâwhich included all enrolled participants regardless of completion statusâthe weight loss figure stood at 15.3%.
By comparison, Lilly’s approved medication Zepbound produced weight reductions ranging from 11% to 13.1% in similar 40-week diabetes studies. Retatrutide’s weight loss data appears superior, though direct comparative trials have not been conducted.
Scotiabank’s analyst Louise Chen characterized the findings as “the highest levels of weight loss we’ve seen from an obesity drug to date” within a patient population known for weight reduction challenges.
Analysts from J.P. Morgan provided a more cautious assessment, highlighting that the drug’s efficacy must be weighed against elevated adverse event rates compared to Lilly’s diabetes medication Mounjaro.
Retatrutide’s Mechanism of Action
Retatrutide is administered as a weekly subcutaneous injection that engages three distinct hormone receptorsâGLP-1, GIP, and glucagonâwhich has led to its informal designation as a “triple-G” therapy. This represents one additional receptor target compared to Zepbound (tirzepatide), which activates GLP-1 and GIP, and two more than Novo Nordisk‘s Wegovy (semaglutide), which exclusively targets GLP-1.
The therapeutic rationale involves simultaneous activation of these three pathways to reduce appetite, regulate glucose metabolism, and enhance metabolic expenditure.
Adverse reactions were predominantly gastrointestinal in nature. Approximately 26.5% of patients receiving the highest dose reported nausea, 22.8% experienced diarrhea, and 17.6% had vomiting episodes. Treatment discontinuation due to adverse effects occurred in up to 5% of participants, which Lilly characterized as comparatively modest.
A limited number of participants reported dysesthesiaâan abnormal unpleasant nerve sensation.
Regulatory Timeline for Lilly
Lilly has not submitted regulatory applications for retatrutide for either obesity or diabetes indications. Thursday’s announcement represents only the second Phase 3 data readout for the compound.
The pharmaceutical company anticipates reporting results from seven more Phase 3 clinical trials throughout 2025, encompassing diverse patient demographics.
Lilly is simultaneously preparing for the commercial launch of its oral obesity medication orforglipron in the second quarter of this year, subject to FDA authorization.
Meanwhile, Novo Nordisk is pursuing competitive strategies. In March 2025, Novo acquired rights to a triple-receptor candidate from United Laboratories International for up to $2 billionâhowever, that asset remains in preliminary development stages and is several years from potential market availability.
Shares of Eli Lilly (LLY) declined modestly in premarket trading Thursday following the trial results announcement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
